List of Excipients in Branded Drug GUAIFENESIN AND DEXTROMETHORPHAN HBR

Generic Drugs Containing GUAIFENESIN AND DEXTROMETHORPHAN HBR

Company	Ingredient	NDC	Excipient
Target Corporation	guaifenesin and dextromethorphan hbr	11673-267	CELLULOSE, MICROCRYSTALLINE
Target Corporation	guaifenesin and dextromethorphan hbr	11673-267	HYPROMELLOSE
Target Corporation	guaifenesin and dextromethorphan hbr	11673-267	MAGNESIUM STEARATE
Target Corporation	guaifenesin and dextromethorphan hbr	11673-267	POVIDONE K25
Target Corporation	guaifenesin and dextromethorphan hbr	11673-267	POVIDONE K90

What are the Most Frequently-Used Excipients in GUAIFENESIN AND DEXTROMETHORPHAN HBR?

# Of NDCs	Excipient
2	CARBOMER HOMOPOLYMER TYPE A
10	CARBOMER HOMOPOLYMER TYPE B
29	CELLULOSE, MICROCRYSTALLINE
2	D&C YELLOW NO. 10
3	FD&C BLUE NO. 1

Guaifenesin and Dextromethorphan HBr Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Guaifenesin and dextromethorphan hydrobromide are mature OTC active ingredients with limited composition-of-matter protection and no biosimilar risk. Commercial value is concentrated in dosage-form performance, taste masking, abuse-deterrent positioning, pediatric usability, private-label manufacturing, and differentiated delivery systems. The strongest opportunities are liquid and orally disintegrating products that improve adherence without creating new FDA regulatory burdens.

What are guaifenesin and dextromethorphan HBr used for?

Guaifenesin is an expectorant used to loosen phlegm and thin bronchial secretions. Dextromethorphan hydrobromide is an antitussive used to temporarily suppress cough. Combination products commonly position the actives for cough associated with mucus and chest congestion.

The combination is generally marketed through the U.S. OTC drug framework rather than through a newly approved prescription product. FDA regulations identify dextromethorphan and guaifenesin as permitted OTC cough and cold active ingredients when used within applicable conditions, concentrations, labeling, and dosage requirements.[1]

Active ingredient	Primary function	Common adult dose range in OTC products	Key formulation issue
Guaifenesin	Expectorant	Often 100-400 mg per immediate-release dose; extended-release products may use 600-1,200 mg twice daily	High dose burden, bitterness, suspension stability
Dextromethorphan HBr	Antitussive	Often 10-20 mg per immediate-release dose or 30 mg every 6-8 hours	Bitter taste, solubility, misuse concerns
Combination	Cough suppression plus mucus relief	Product-specific	Taste, viscosity, preservative, dosing accuracy, label compliance

Actual strengths vary by product and dosage form. The Drug Facts label and applicable FDA conditions control the marketed claim set.

What excipients are best suited to this combination?

The optimal excipient system depends on whether the product is a liquid, tablet, capsule, orally disintegrating tablet, chewable, or extended-release dosage form. A single excipient platform is unlikely to perform equally well across all formats.

Immediate-release oral liquids

Immediate-release liquids offer the broadest commercial opportunity because they permit flexible dosing, pediatric-oriented presentation, and rapid product differentiation.

A typical liquid platform may include:

Function	Candidate excipients	Commercial and technical considerations
Solvent	Purified water, glycerin, propylene glycol, polyethylene glycol	Controls solubilization, mouthfeel, and viscosity
Sweetener	Sucrose, sorbitol, high-intensity sweeteners, sucralose, acesulfame potassium	Sugar-free products require careful control of aftertaste and laxation risk
Taste masking	Flavors, cyclodextrins, ion-exchange resins, polymeric coatings	Dextromethorphan bitterness is usually the dominant sensory challenge
Viscosity	Xanthan gum, sodium carboxymethylcellulose, hydroxyethylcellulose	Supports suspension uniformity and mouthfeel
Buffer	Citrate, phosphate, acetate systems	pH affects taste, preservative performance, and active stability
Preservative	Sodium benzoate, potassium sorbate, parabens where appropriate	Must be selected against pH and microbial challenge results
Chelator	Disodium EDTA	Can improve preservative robustness in some aqueous systems
Wetting agent	Polysorbates, poloxamers	Useful where guaifenesin or flavor components require improved dispersion
Color	Approved color additives	Supports brand differentiation but creates labeling and sensitivity-management issues

Dextromethorphan HBr is water soluble enough for many aqueous formulations, but the combined sensory profile can remain difficult. Guaifenesin contributes a medicinal taste and increases solids burden. Sweetener intensity alone may not solve the problem because it can leave a bitter or cooling aftertaste.

The strongest formulation strategy uses layered taste control: pH adjustment, flavor architecture, viscosity modulation, and a targeted masking technology. Cyclodextrins or ion-exchange resins can support premium products, but they add cost, process complexity, and potential regulatory documentation.

Extended-release liquids

Extended-release dextromethorphan products use polymeric systems to sustain release. Guaifenesin may be included as an immediate-release component or paired with a separate release phase.

Relevant excipients include:

• Hypromellose
• Carbomers
• Xanthan gum
• Microcrystalline cellulose
• Polyvinyl acetate-based systems
• Ion-exchange resins
• Suspending agents and controlled-flocculation systems

An extended-release liquid requires tight control of particle size, sedimentation, redispersibility, dose uniformity, and release profile. The principal commercial advantage is reduced dosing frequency. The principal risk is manufacturing variability, especially after scale-up or changes in raw-material grade.

Tablets, caplets, and capsules

Solid dosage forms can reduce preservative use and simplify shipping. Their main constraints are dose size and swallowability, particularly when guaifenesin is used at higher strength.

Common excipient categories include:

• Fillers such as microcrystalline cellulose, lactose, mannitol, and dibasic calcium phosphate
• Binders such as povidone and pregelatinized starch
• Disintegrants such as croscarmellose sodium, crospovidone, and sodium starch glycolate
• Lubricants such as magnesium stearate and sodium stearyl fumarate
• Film coatings based on hypromellose or polyvinyl alcohol
• Opacifiers and colorants

For immediate-release tablets, rapid disintegration and adequate dissolution are the main objectives. Excessive lubricant use can slow wetting and dissolution. High tablet weight can also reduce consumer acceptance even when the active ingredients are clinically familiar.

Orally disintegrating and chewable products

Orally disintegrating tablets and chewables create an opportunity in consumers who have difficulty swallowing conventional tablets or who want a portable product.

Mannitol is commonly used for its cooling mouthfeel and low hygroscopicity. Crospovidone, low-substituted hydroxypropyl cellulose, and co-processed excipients can support rapid disintegration. Taste masking is essential because the dosage form remains in the mouth.

Chewable products require stronger control of:

• Dextromethorphan bitterness
• Guaifenesin chalkiness
• Residual mouth coating
• Tablet hardness
• Moisture uptake
• Flavor stability

A chewable product with inadequate taste masking can lose repeat purchase even if its pharmacological performance is equivalent to competing products.

What formulation patents can protect guaifenesin and dextromethorphan products?

The active ingredients are old and generally do not provide meaningful new-chemical-entity exclusivity. Commercial protection is more likely to arise from formulation, manufacturing, packaging, or brand-specific claims.

Potentially protectable subject matter includes:

1. Extended-release matrices that produce a defined dextromethorphan release profile.
2. Bilayer tablets separating immediate-release guaifenesin from sustained-release dextromethorphan.
3. Taste-masked particles using resins, lipids, polymers, or coating systems.
4. Stable aqueous suspensions with defined particle-size distributions and redispersibility.
5. Low-sugar or sugar-free formulations with specified preservative and pH systems.
6. Abuse-deterrent formulations that limit extraction or rapid release.
7. Unit-dose sachets, stick packs, dosing cups, and child-resistant delivery systems.
8. Manufacturing processes that improve content uniformity or reduce active degradation.

Patent value depends on claim scope and design-around difficulty. A broad claim covering a functional result such as "taste-masked dextromethorphan" may face validity and enablement pressure. Narrow claims tied to specific polymers, ratios, particle sizes, or process conditions may be easier to defend but simpler to design around.

How strong is the patent estate for this combination?

The baseline patent estate is weak for the active ingredients and stronger only where a product incorporates a differentiated delivery platform. Guaifenesin and dextromethorphan have been used in OTC products for decades, so broad ingredient claims and ordinary combination claims are unlikely to provide durable exclusivity.

Protection category	Expected strength	Strategic value
Guaifenesin composition of matter	Very low	Minimal
Dextromethorphan HBr composition of matter	Very low	Minimal
Basic two-active combination	Low	Limited
Extended-release delivery	Moderate to high if technically narrow and validated	Meaningful
Taste masking	Moderate	Useful for premium products
Pediatric liquid platform	Low to moderate	Supports brand differentiation
Packaging and dosing system	Low to moderate	Useful for trade dress and lifecycle management
Manufacturing process	Moderate if difficult to replicate	May support supply advantage
Brand and private-label positioning	Commercial rather than patent-based	Often more important than patents

A product-specific freedom-to-operate review should distinguish patents covering the active pharmaceutical ingredients from patents covering dosage-form architecture, excipient combinations, process parameters, and packaging.

What is the FDA regulatory status and Orange Book position?

Most guaifenesin-dextromethorphan OTC products are regulated under the FDA’s OTC framework, including applicable monograph conditions and labeling requirements. A product that conforms to the relevant OTC requirements does not need the same type of product-specific efficacy approval associated with a new prescription NDA.

The Orange Book is primarily relevant to approved drug applications and listed patents submitted under the Hatch-Waxman framework. Standard OTC monograph products generally do not receive the same Orange Book patent-listing profile as prescription drugs approved through NDAs.[2]

An individual product may have a different regulatory status if it is marketed under an NDA, has a prescription history, or uses a delivery system outside the applicable OTC conditions. The regulatory pathway must therefore be assessed at the product level.

Does the combination face Paragraph IV challenges?

A conventional OTC monograph product generally does not create the same Paragraph IV litigation pathway as an NDA product with Orange Book-listed patents. Paragraph IV risk becomes more relevant where a specific approved application has listed patents or where a follow-on applicant relies on an NDA framework.

For standard OTC products, competitive threats are more likely to arise from:

• Private-label substitution
• Retailer exclusivity
• Contract manufacturing
• Trademark disputes
• Formulation patents
• State and federal labeling enforcement
• Product recalls and manufacturing failures

When do guaifenesin and dextromethorphan products lose exclusivity?

The principal active-ingredient exclusivity periods expired decades ago. There is no ordinary remaining composition-of-matter exclusivity for a conventional guaifenesin and dextromethorphan HBr product.

Commercial exclusivity can still persist through:

• A formulation patent with a later expiration date
• A proprietary extended-release system
• Trade secrets covering taste masking or manufacturing
• A strong national brand
• Retailer or pharmacy-channel contracts
• Regulatory investment in a differentiated dosage form
• Consumer recognition and distribution scale

The loss of formal patent exclusivity does not necessarily eliminate pricing power. It shifts the basis of competition from legal exclusivity to manufacturing cost, channel access, sensory performance, packaging, and brand trust.

What manufacturing and IP barriers affect this market?

Manufacturing barriers are more practical than molecule-level patent barriers.

Liquid manufacturing barriers

Liquid products require validated control of:

• Active dissolution or dispersion
• pH
• Viscosity
• Microbial limits
• Preservative effectiveness
• Sedimentation and redispersion
• Fill-volume accuracy
• Flavor and color uniformity

Guaifenesin can create high solids loading, while flavor systems can interact with preservatives, polymers, and packaging materials. Extractables and leachables risk is relevant for plastic bottles, closures, dosing devices, and unit-dose packaging.

Solid manufacturing barriers

Tablets and capsules require control of:

• Blend uniformity
• Segregation
• Compression force
• Tablet weight and hardness
• Disintegration and dissolution
• Coating uniformity
• Moisture sensitivity

A high-dose guaifenesin tablet can create a large unit and may require a multilayer or multiparticulate design.

Supply-chain barriers

Commercial suppliers must manage:

• API availability and quality
• Excipient grade consistency
• Flavor and sweetener supply
• Packaging component lead times
• Seasonal demand
• Contract manufacturing capacity
• Recall readiness

Cough and cold demand is seasonal and can produce sharp inventory swings. A low-cost formulation with poor supply resilience can lose market share during peak demand.

What commercial opportunities exist for this combination?

Premium taste-masked liquids

Taste-masked, sugar-free liquids can command higher retail prices if they deliver better palatability and dosing convenience. This segment is suited to adult, pediatric, and caregiver-oriented positioning.

The commercial advantage is strongest when taste improvement is measurable through sensory testing and paired with a stable preservative system.

Extended-release products

Once- or twice-daily products can differentiate from conventional four-hour or six-hour dosing. The opportunity is greatest where the release profile remains consistent across fed and fasted conditions and where the label provides a clear dosing benefit.

Pediatric and family products

Pediatric products require careful label positioning, dosing-device design, and age-related compliance. The FDA has advised against cough and cold products containing certain active ingredients for children under two and supports caution for young children under product-specific labeling.[3]

Opportunities include:

• Unit-dose oral syringes
• Dosing cups with high legibility
• Child-resistant packaging
• Dye-free formulations
• Sugar-free formulations
• Lower-volume concentrated liquids
• Age-segmented flavor systems

Private-label and contract manufacturing

Retail pharmacies, grocery chains, mass merchants, and e-commerce sellers can use the combination in store brands. The most competitive suppliers offer:

• Multiple dosage forms from one platform
• Rapid label and packaging customization
• Reliable seasonal capacity
• Stable cost of goods
• Monograph-compliant documentation
• Recall and complaint-handling systems

Private-label margins are usually lower than branded margins, but volume and retailer access can offset price pressure.

Abuse-deterrent and responsible-use positioning

Dextromethorphan misuse is a known public-health issue. Formulations that reduce rapid extraction, discourage excessive consumption, or improve package controls may have commercial and regulatory value. Claims must be supported by technical evidence and must not imply unsupported safety benefits.

E-commerce and travel formats

Single-dose sachets, stick packs, pocket bottles, and blister-packed chewables can support online and travel channels. Packaging must address child resistance, leakage, tamper evidence, and dosing accuracy.

How does this combination compare with competing cough products?

Product category	Main active	Consumer benefit	Competitive weakness
Guaifenesin alone	Guaifenesin	Mucus relief	Does not suppress cough
Dextromethorphan alone	Dextromethorphan HBr	Cough suppression	Does not target mucus
Combination	Both actives	Broad cough-and-chest-congestion positioning	Higher taste and dose complexity
Dextromethorphan extended release	Dextromethorphan HBr	Reduced dosing frequency	More complex formulation
Multi-symptom cough and cold	Several actives	Broad symptom coverage	Greater side-effect and labeling complexity
Honey or non-drug products	Non-drug	Perceived natural positioning	Limited applicability and variable evidence

The two-active combination has a clear consumer proposition but faces substitution from single-ingredient products and multi-symptom products. A focused label can be commercially advantageous because it avoids unnecessary active ingredients.

What litigation and settlement issues affect the market?

No ordinary patent settlement framework dominates the conventional OTC combination market. Litigation exposure is more likely to involve:

• Product liability
• Mislabeling
• Manufacturing deviations
• Class actions over pediatric use or dosing
• Trademark and trade dress
• Advertising claims
• Patent disputes over extended-release or taste-masking technology

A company launching a differentiated formulation should review issued patents and pending applications covering release systems, resin complexes, polymer matrices, liquid suspensions, and abuse-deterrent technologies. A generic or private-label launch can often avoid risk by using a conventional monograph-compliant formulation rather than copying a branded delivery platform.

What revenue exposure and launch scenarios should investors evaluate?

Public companies rarely disclose revenue specifically for guaifenesin-dextromethorphan combinations. Revenue analysis therefore depends on brand, channel, dosage form, and seasonal sell-through rather than on molecule-level market exclusivity.

Launch scenario	Entry condition	Margin profile	Main risk
Conventional private-label syrup	Monograph-compliant formula and retailer contract	Low to moderate	Price competition
Premium sugar-free liquid	Improved taste and packaging	Moderate to high	Sensory failure or higher COGS
Extended-release product	Validated release technology	High if differentiated	Development and patent risk
ODT or chewable	Strong taste-masking platform	Moderate to high	Consumer acceptance
Multi-channel branded product	Brand investment and distribution	Variable	Marketing cost
Contract-manufactured seasonal line	Existing capacity and flexible packaging	Moderate	Demand volatility

The highest-return opportunity is usually not another standard syrup. It is a product with one of three defensible advantages: reduced dosing frequency, materially better taste, or a lower-cost and more reliable supply model.

What geographic coverage and international issues matter?

The active ingredients are used in multiple international markets, but regulatory status, permitted indications, dose limits, labeling, and pediatric restrictions vary by country.

Key differences may involve:

• OTC versus prescription classification
• Permitted dextromethorphan strengths
• Combination restrictions
• Age limitations
• Alcohol content
• Sugar and allergen labeling
• Approved preservatives and colors
• Local pharmacovigilance requirements
• Import and GMP expectations

A formulation designed for the United States may require reformulation for the European Union, Canada, Australia, or selected Asian markets. Dextromethorphan controls and abuse-prevention requirements can also differ by jurisdiction.

Key Takeaways

• Guaifenesin and dextromethorphan HBr have minimal active-ingredient exclusivity remaining.
• The commercial opportunity is formulation-led, not molecule-led.
• Taste masking is the central excipient challenge, particularly in liquids, chewables, and orally disintegrating tablets.
• Extended-release systems offer the strongest potential for differentiation but carry greater development and patent risk.
• Sugar-free, dye-free, pediatric-oriented, and portable formats support retail and e-commerce opportunities.
• Standard monograph products generally do not present the same Orange Book and Paragraph IV profile as NDA-based prescription products.
• Manufacturing reliability, seasonal capacity, packaging, and retailer access can matter more than patent ownership.
• Biosimilar risk is irrelevant because both actives are small-molecule drugs, not biologics.
• The strongest launch candidates combine improved sensory performance with a clear dosing or packaging advantage.

FAQs about guaifenesin and dextromethorphan HBr formulation strategy

Can cyclodextrins improve dextromethorphan taste?

Yes. Cyclodextrins can reduce free drug interaction with taste receptors, but the effect depends on complexation efficiency, dose, pH, and the final flavor system. They may increase formulation cost and require assessment of dissolution and bioavailability.

Is a sugar-free guaifenesin-dextromethorphan syrup commercially viable?

Yes. Sugar-free products can target adults, diabetic consumers, and caregivers seeking lower-sugar options. Sorbitol, glycerin, and high-intensity sweeteners must be balanced against laxation potential, viscosity, and aftertaste.

Which excipient is best for suspending guaifenesin?

No single excipient is universally optimal. Xanthan gum, sodium carboxymethylcellulose, microcrystalline cellulose systems, and combinations of suspending agents are common starting points. Selection depends on particle size, density, viscosity, redispersibility, and sensory requirements.

Does dextromethorphan HBr require an abuse-deterrent formulation?

A conventional OTC product does not automatically require abuse-deterrent technology. Abuse-deterrent features may create differentiation, but the manufacturer must avoid unsupported claims and validate the technology against the intended misuse pathway.

Can a company patent a new guaifenesin-dextromethorphan syrup?

A company may obtain patent protection for a genuinely novel and non-obvious formulation, release system, manufacturing process, or packaging configuration. A routine mixture of known actives and conventional excipients is less likely to support strong patent claims.

References

1. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-over-counter-drugs

3. U.S. Food and Drug Administration. (2018). Use cautions when giving cough and cold products to kids. https://www.fda.gov/drugs/special-features/use-caution-when-giving-cough-and-cold-products-kids